253 related articles for article (PubMed ID: 21396519)
1. [Long-term psoriasis treatment].
Jullien D; Battistella M
Ann Dermatol Venereol; 2011 Feb; 138(2 Suppl 1):H15-8. PubMed ID: 21396519
[No Abstract] [Full Text] [Related]
2. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
[TBL] [Abstract][Full Text] [Related]
3. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis.
Tan X; Balkrishnan R; Feldman SR
J Drugs Dermatol; 2013 Mar; 12(3):e41-5. PubMed ID: 23545925
[TBL] [Abstract][Full Text] [Related]
4. Advertisements for TNF Inhibitors.
Med Lett Drugs Ther; 2008 Nov; 50(1299):89. PubMed ID: 19008788
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.
Viguier M; Aubin F; Delaporte E; Pagès C; Paul C; Beylot-Barry M; Goujon C; Rybojad M; Bachelez H;
Arch Dermatol; 2012 Dec; 148(12):1423-5. PubMed ID: 23247492
[No Abstract] [Full Text] [Related]
6. [What is the impact of the new clinical trial data? What are the lessons for patient management?].
Passeron T; Boulinguez S
Ann Dermatol Venereol; 2010 May; 137(5 Suppl 1):11-5. PubMed ID: 20510174
[No Abstract] [Full Text] [Related]
7. Treatment of spondyloarthritides with anti-TNFalpha biologic agents.
Braun J
Reumatismo; 2006; 58 Spec No.1():71-2. PubMed ID: 23631067
[No Abstract] [Full Text] [Related]
8. Is there a benefit from using a subsequent anti-TNF α medication in psoriasis patients who failed their first or second anti-TNF α agent?
Alsharqi A; Parslew R; Dever B; Arslanian V
Australas J Dermatol; 2012 May; 53(2):e45-7. PubMed ID: 22571585
[No Abstract] [Full Text] [Related]
9. Anti-TNF agents for the treatment of psoriasis.
Kircik LH; Del Rosso JQ
J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
[TBL] [Abstract][Full Text] [Related]
10. Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
Carlesimo M; La Pietra M; Arcese A; Di Russo PP; Mari E; Gamba A; Orsini D; Camplone G
Int J Dermatol; 2012 Oct; 51(10):1234-6. PubMed ID: 22416995
[No Abstract] [Full Text] [Related]
11. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors.
Meyer MW; Zachariae C; Bendtzen K; Skov L
Acta Derm Venereol; 2012 Jul; 92(4):362-4. PubMed ID: 22864558
[No Abstract] [Full Text] [Related]
12. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
[TBL] [Abstract][Full Text] [Related]
13. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis.
Langley RG; Strober BE; Gu Y; Rozzo SJ; Okun MM
Br J Dermatol; 2010 Jun; 162(6):1349-58. PubMed ID: 20394634
[TBL] [Abstract][Full Text] [Related]
14. [European and British recommendations on the role of biologic interventions in moderate to severe psoriasis].
Bachelez H; Battistella M
Ann Dermatol Venereol; 2011 Apr; 138(2 Suppl 2):H14-7. PubMed ID: 21703457
[No Abstract] [Full Text] [Related]
15. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
16. Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis.
Capo A; Di Nicola M; Auriemma M; Piaserico S; Cuccurullo C; Santilli F; Davi G; Amerio P
Eur J Dermatol; 2014; 24(1):133-5. PubMed ID: 24589526
[No Abstract] [Full Text] [Related]
17. Viewpoint on handling anti-TNF failure in psoriasis.
Bracke S; Lambert J
Arch Dermatol Res; 2013 Dec; 305(10):945-50. PubMed ID: 24096701
[TBL] [Abstract][Full Text] [Related]
18. Treatment of nail psoriasis with tumor necrosis factor-alpha blocker agents: an open-label, unblinded, comparative study.
Ozmen I; Erbil AH; Koc E; Tunca M
J Dermatol; 2013 Sep; 40(9):755-6. PubMed ID: 23834032
[No Abstract] [Full Text] [Related]
19. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment.
Van L; Modi SV; Yang DJ; Hsu S
Arch Dermatol; 2008 Jun; 144(6):804-6. PubMed ID: 18559778
[No Abstract] [Full Text] [Related]
20. Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors.
Egnatios G; Warthan MM; Pariser R; Hood AF
J Drugs Dermatol; 2008 Oct; 7(10):975-7. PubMed ID: 19112764
[No Abstract] [Full Text] [Related]
[Next] [New Search]
